Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
UBS
Chubb
Fish and Richardson
Johnson and Johnson
Chinese Patent Office
Cerilliant
Healthtrust

Generated: December 10, 2018

DrugPatentWatch Database Preview

LEMTRADA Drug Profile

« Back to Dashboard

Summary for Tradename: LEMTRADA
Patents:301
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for LEMTRADA

US Patents for LEMTRADA

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Bayer Intellectual Property GMBH (Monheim, DE) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Alexion Pharmaceuticals, Inc. (New Haven, CT) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Genentech, Inc. (South San Francisco, CA) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Centogene AG (Rostock, DE) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Beth Israel Deaconess Medical Center, Inc. (Boston, MA) Emory University (Atlanta, GA) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for LEMTRADA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016019 Lithuania ➤ Sign Up PRODUCT NAME: ALEMTUZUMABAS; REGISTRATION NO/DATE: EU/1/13/869 20130912
2016000049 Germany ➤ Sign Up PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
2016022 Lithuania ➤ Sign Up PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
2018502 Lithuania ➤ Sign Up PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822
780 Luxembourg ➤ Sign Up PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
/2016 Austria ➤ Sign Up PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 (MITTEILUNG) 20130916
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
UBS
Fuji
McKinsey
Healthtrust
Dow
Boehringer Ingelheim
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.